Aesthetic surgery journal
September 10, 2026 · via Europe PMC
Proteomic Profiling of Breast Implant Capsules: a Novel Approach for Studying Biocompatibility and Capsular Contracture.
Larsen A, Østergaard O, Weltz TK, +8 more, Herly M.
AI summary — for doctors, generated from the abstract only
A proof-of-concept proteomic study of breast implant capsules found that samples from patients with capsular contracture had a distinct molecular profile compared with non-contracture controls, dominated by extracellular matrix remodeling and immune activation signatures.
What was studied
A case-control study comparing deep proteomic profiles (via mass spectrometry) of breast implant capsule biopsies from women with capsular contracture (Baker III/IV, n=24) versus non-contracture controls (Baker I, n=24), using differential expression, co-expression network, and functional enrichment analyses alongside histopathological scoring.
Key findings
- Deep proteomic profiling quantified 7,258 proteins (median 5,879 per sample); unsupervised analyses separated contracture from control samples without prior grouping information (P=0.001), indicating a distinct contracture-associated proteome.
- 77 differentially expressed proteins were identified (31 upregulated, 46 downregulated), with extracellular matrix remodeling proteins MMP9, TIMP1, and TIMP3 among the changes.
- A profibrotic TGF-β signature (THBS1, THBS2, periostin, TGM2) and innate immune activation markers (MPO, FCGR1A, S100A8, S100A9) were identified, along with a contracture-associated neutrophil degranulation module and an adaptive immune module linked to implantation time and rupture.
Clinical relevance
This proof-of-concept study suggests that specific molecular pathways (ECM remodeling, TGF-β signaling, immune activation) may underlie capsular contracture, which may be relevant to future research into biomarkers or targeted prevention strategies, though this is exploratory molecular research, not a clinical intervention study.
Who should care
Limitations
This is a case-control proteomic study with a modest sample size (24 per group) designed to establish feasibility (proof-of-concept) rather than test a clinical intervention; it cannot establish whether the identified molecular changes cause contracture or occur as a consequence of it.
Proteomic profiling revealed a distinct molecular signature in breast implant capsules associated with capsular contracture, involving ECM remodeling and immune activation.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Background
Standardized molecular methods to assess the host response to breast implants are lacking. Mass spectrometry-based proteomics offers an unbiased approach to characterize the capsule proteome and the foreign-body response.
Objectives
To establish proof-of-concept for deep proteomic profiling of human breast implant capsule tissue and explore the proteomic profile associated with capsular contracture.
Methods
Capsule biopsies were obtained from women with capsular contracture (Baker III/IV, n = 24) and non-contracture controls (Baker I, n = 24). Proteomic profiles were analyzed by liquid chromatography-tandem mass spectrometry with label-free quantification. Differential expression, co-expression network, and functional enrichment analyses were performed, and capsules were additionally scored with a validated histopathological system.
Results
Deep proteomic profiling quantified 7,258 proteins (median 5,879 per sample). Unsupervised analyses separated contracture from control samples without prior grouping information, indicating a distinct contracture-associated proteome (P = 0.001). We identified 77 differentially expressed proteins (31 upregulated, 46 downregulated). Extracellular matrix (ECM) remodeling dominated, with upregulation of MMP9 and inhibitors TIMP1 and TIMP3. A profibrotic TGF-β signature included THBS1, THBS2, periostin, and TGM2, and innate immune activation included MPO, FCGR1A, S100A8, and S100A9. Co-expression network analysis identified a contracture-associated neutrophil degranulation module, and an adaptive immune module linked to implantation time and rupture.
Conclusion
Deep proteomic profiling of human breast implant capsules is feasible and revealed a contracture-associated proteomic phenotype dominated by ECM dysregulation, a profibrotic TGF-beta axis, and innate and adaptive immune activation. These findings provide proof-of-concept for capsule proteomics as a tool to study the host response to breast implants.
DOI
10.1093/asj/sjag186
PMID
42717641
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed